Med-IQ CME: The Future Potential of Factor XI/XIa Inhibitors to Address Stroke Risk in AF
In this CME activity, discover the latest information on investigational factor XI/XIa inhibitors, including results from completed clinical trials and news about ongoing clinical trials, to explore their potential role in managing stroke risk in patients with atrial fibrillation (AF).
Cost: Free
View Offer chevron_rightKey Features
Explore the latest data from completed and ongoing clinical trials on investigational factor XI/XIa inhibitors and their potential role in managing stroke risk in patients with AF.
Topics Covered
XI/XIa Inhibitors for managing stroke risk in patients with atrial fibrillation
Learning Objectives
1. Differentiate factor XI/XIa inhibitors from available anticoagulants
2. Articulate the potential impact of emerging clinical data for the safety and efficacy of factor XI/XIa inhibitors in the prevention of stroke in patients with AF
Target Audience
This activity is intended primarily for cardiologists and other clinicians involved in the care of patients with AF.
Additional credit info
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.